These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 23083608)

  • 1. Malignant transformation: the role of MRS.
    Jiang L; Wijnen JP; Glunde K
    Eur J Radiol; 2012 Sep; 81 Suppl 1():S66-8. PubMed ID: 23083608
    [No Abstract]   [Full Text] [Related]  

  • 2. L-COSY of breast cancer at 3T.
    Ramadan S; Baltzer PA; Lin A; Stanwell P; Box H; Kaiser WA; Mountford CE
    Eur J Radiol; 2012 Sep; 81 Suppl 1():S129-31. PubMed ID: 23083559
    [No Abstract]   [Full Text] [Related]  

  • 3. What is new in breast MRI spectroscopy.
    Nelson MT; Bolan PJ; Garwood M; Everson L; Emory T; Kuehn-Hajder J
    Eur J Radiol; 2012 Sep; 81 Suppl 1():S107-8. PubMed ID: 23083548
    [No Abstract]   [Full Text] [Related]  

  • 4. Quantitative multivoxel proton chemical shift imaging of the breast.
    Sijens PE; Dorrius MD; Kappert P; Baron P; Pijnappel RM; Oudkerk M
    Magn Reson Imaging; 2010 Apr; 28(3):314-9. PubMed ID: 20071119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CEST-imaging: A new contrast in MR-mammography by means of chemical exchange saturation transfer.
    Schmitt B; Trattnig S; Schlemmer HP
    Eur J Radiol; 2012 Sep; 81 Suppl 1():S144-6. PubMed ID: 23083567
    [No Abstract]   [Full Text] [Related]  

  • 6. Magnetic resonance spectroscopy of the breast: current status.
    Bolan PJ
    Magn Reson Imaging Clin N Am; 2013 Aug; 21(3):625-39. PubMed ID: 23928249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A qualitative approach to combined magnetic resonance imaging and spectroscopy in the diagnosis of prostate cancer.
    Villeirs GM; Oosterlinck W; Vanherreweghe E; De Meerleer GO
    Eur J Radiol; 2010 Feb; 73(2):352-6. PubMed ID: 19084363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noninvasive evaluation of cerebral glioma grade by using multivoxel 3D proton MR spectroscopy.
    Zeng Q; Liu H; Zhang K; Li C; Zhou G
    Magn Reson Imaging; 2011 Jan; 29(1):25-31. PubMed ID: 20832225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MR spectroscopy of head and neck cancer.
    Abdel Razek AA; Poptani H
    Eur J Radiol; 2013 Jun; 82(6):982-9. PubMed ID: 23485098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proton magnetic resonance spectroscopy of musculoskeletal lesions at 3 T with metabolite quantification.
    Lee CW; Lee JH; Kim DH; Min HS; Park BK; Cho HS; Kang HG; Suh JS; Ehara S
    Clin Imaging; 2010; 34(1):47-52. PubMed ID: 20122519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MR spectroscopy in the breast clinic is improving.
    Mountford CE; Schuster C; Baltzer PA; Malycha P; Kaiser WA
    Eur J Radiol; 2012 Sep; 81 Suppl 1():S104-6. PubMed ID: 23083547
    [No Abstract]   [Full Text] [Related]  

  • 12. Detection of prostate cancer with MR spectroscopic imaging: an expanded paradigm incorporating polyamines.
    Shukla-Dave A; Hricak H; Moskowitz C; Ishill N; Akin O; Kuroiwa K; Spector J; Kumar M; Reuter VE; Koutcher JA; Zakian KL
    Radiology; 2007 Nov; 245(2):499-506. PubMed ID: 17890357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo magnetic resonance spectroscopy of gynaecological tumours at 3.0 Tesla.
    Booth SJ; Pickles MD; Turnbull LW
    BJOG; 2009 Jan; 116(2):300-3. PubMed ID: 19076962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer: identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging--correlation with pathologic findings.
    Mazaheri Y; Shukla-Dave A; Hricak H; Fine SW; Zhang J; Inurrigarro G; Moskowitz CS; Ishill NM; Reuter VE; Touijer K; Zakian KL; Koutcher JA
    Radiology; 2008 Feb; 246(2):480-8. PubMed ID: 18227542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterisation of in vivo ovarian cancer models by quantitative 1H magnetic resonance spectroscopy and diffusion-weighted imaging.
    Canese R; Pisanu ME; Mezzanzanica D; Ricci A; Paris L; Bagnoli M; Valeri B; Spada M; Venditti M; Cesolini A; Rodomonte A; Giannini M; Canevari S; Podo F; Iorio E
    NMR Biomed; 2012 Apr; 25(4):632-42. PubMed ID: 22020805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinally monitoring chemotherapy effect of malignant musculoskeletal tumors with in vivo proton magnetic resonance spectroscopy: an initial experience.
    Hsieh TJ; Li CW; Chuang HY; Liu GC; Wang CK
    J Comput Assist Tomogr; 2008; 32(6):987-94. PubMed ID: 19204465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The infrared spectral signatures of disease: extracting the distinguishing spectral features between normal and diseased states.
    Diem M; Papamarkakis K; Schubert J; Bird B; Romeo MJ; Miljković M
    Appl Spectrosc; 2009 Nov; 63(11):307A-318A. PubMed ID: 19891826
    [No Abstract]   [Full Text] [Related]  

  • 18. The value of proton MR-spectroscopy in the differentiation of brain tumours from non-neoplastic brain lesions.
    Aydin H; Sipahioğlu S; Oktay NA; Altin E; Kizilgöz V; Hekimoglu B
    JBR-BTR; 2011; 94(1):1-10. PubMed ID: 21466053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantification of prostate MRSI data by model-based time domain fitting and frequency domain analysis.
    Pels P; Ozturk-Isik E; Swanson MG; Vanhamme L; Kurhanewicz J; Nelson SJ; Van Huffel S
    NMR Biomed; 2006 Apr; 19(2):188-97. PubMed ID: 16411280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proton MR spectroscopy with choline peak as malignancy marker improves positive predictive value for breast cancer diagnosis: preliminary study.
    Bartella L; Morris EA; Dershaw DD; Liberman L; Thakur SB; Moskowitz C; Guido J; Huang W
    Radiology; 2006 Jun; 239(3):686-92. PubMed ID: 16603660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.